InterMune (nasdaq)ITMN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (441)	1/10/2009 6:30:54 AM
From: ghmm	of 508

I think a lot of huff-n-puffers (as elsewhere) didn't meet the entry criteria. Anecdotally there seem to be a lot of people waiting for the drug to be approved even if though they may hate InterMune. A small US phase 2 (open label and at a much higher dose 3600mg) was done in very advanced patients and had very encouraging results. If the drug is approved, I would think insurance would pay for these without much trouble. If the data is very good (FVC and PFS at a minimum) I think the drug will do very well. I am actually concerned that the mild patient class doesn't progress as rapidly and with being in a study/better care even the placebo do better. Was happy to see Welch increase the size and especially add 12 more weeks (20 more then Shionogi) at least gives a better chance.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next